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SUPPORT-AF: Piloting a Multi-Faceted, Electronic Medical Record-
Based Intervention to Improve Prescription of Anticoagulation
Alok Kapoor, MD, MSc; Azraa Amroze, BS; Jessica Golden, MPH; Sybil Crawford, PhD; Kevin O’Day, MD; Rasha Elhag, MD; Ahmed Nagy,
MD; Steve A. Lubitz, MD, MPH; Jane S. Saczynski, PhD; Jomol Mathew, PhD; David D. McManus, MD, MSc
Background-—Only 50% of eligible atrial ﬁbrillation (AF) patients receive anticoagulation (AC). Feasibility and effectiveness of
electronic medical record (EMR)–based interventions to proﬁle and raise provider AC percentage is poorly understood. The
SUPPORT-AF (Supporting Use of AC Through Provider Proﬁling of Oral AC Therapy for AF) study aims to improve rates of adherence
to AC guidelines by developing and delivering supportive tools based on the EMR to providers treating patients with AF.
Methods and Results-—We emailed cardiologists and community-based primary care providers afﬁliated with our institution
reports of their AC percentage relative to peers. We also sent an electronic medical record–based message to these providers the
day before an appointment with an atrial ﬁbrillation patient who was eligible but not receiving AC. The electronic medical record
message asked the provider to discuss AC with the patient if he or she deemed it appropriate. To assess feasibility, we tracked
provider review of our correspondence. We also tracked the change in AC for intervention providers relative to alternate primary
care providers not receiving our intervention. We identiﬁed 3786, 1054, and 566 patients cared for by 49 cardiology providers, 90
community-based primary care providers, and 88 control providers, respectively. At baseline, the percentage of AC was 71.3%,
63.5%, and 58.3% for these 3 respective groups. Intervention providers reviewed our e-mails and electronic medical record
messages 45% and 96% of the time, respectively. For providers responding, patient refusal was the most common reason for
patients not being on AC (21%) followed by high bleeding risk (19%). At follow-up 10 weeks later, change in AC was no different for
either cardiology or community-based primary care providers relative to controls (0.2% lower and 0.01% higher, respectively).
Conclusions-—Our intervention proﬁling AC was feasible, but not sufﬁcient to increase AC in our population. ( J Am Heart Assoc.
2018;7:e009946. DOI: 10.1161/JAHA.118.009946.)
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A trial ﬁbrillation (AF) currently affects 5.2 million Amer-icans, with 12 million projected by 2050.1–3 AF
accounts for 15% of all ischemic strokes and one third of all
strokes in the elderly.4 These strokes result in permanent
disability in 60% of patients and death in up to 20%.5
Anticoagulation (AC) therapy is the cornerstone for stroke
prevention in patients with AF. However, only around half of
eligible patients receive AC in contemporary US-based,
ambulatory registries.6
Providers and patients struggle with the decision to
initiate AC in new cases of AF or resume AC in patients
previously on it. The American Heart Association/American
College of Cardiology guidelines advise providers about
stroke risk, recommending initiation of AC for eligible
patients (ie, those with a stroke risk CHA2DS2-VASc score
of 2 or higher).7 Providers often point to concerns about
complications from AC in older, frail patients and prohibitive
bleeding risks as reasons for not prescribing AC, but data
show that physicians often overestimate risks of bleeding
and falling and underestimate risks of stroke.6 Although
much work has been done to educate providers about the
risks of undertreatment, an “AC treatment gap” between
eligible and treated AF patients persists, leading to signif-
icant morbidity and mortality.8,9
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Recently, the American College of Cardiology began
collecting AC data from cardiovascular specialists through
the PINNACLE (Practice Innovation and Clinical Excellence)
registry. Initial ﬁndings from the PINNACLE registry conﬁrm
the low prescription percentage found in previous studies
and help to identify undertreatment of AF as a national
problem.10 Although the PINNACLE registry provides a ﬁrst
step toward identifying the gap in AC prescription, raising
percentages will likely require more-structured interventions
that will need to be integrated into individual healthcare
system electronic medical record (EMR) and provider
workﬂows. Previous work by 1 of our team members
(S.L.) has determined that identifying patients with AF and
their stroke risk using the EMR is feasible.11 We built on
that work to test whether e-mailing providers reports with
the percentage of AC they prescribed relative to peers was
feasible. In addition, we assessed whether sending providers
EMR-based messages to notify them of an upcoming
appointment with an eligible AF patient not on AC was
also feasible. Finally, we assessed the effectiveness of our
intervention by measuring the change in AC percentage by
provider over a short time period available to us before the
rollout of a new EMR. In contrast to the PINNACLE registry,
we include primary care providers (in addition to cardiology
providers) in our intervention in order to understand their
contribution to AC decision making. Our intervention also
stands in contrast to 3 recent publications12–14 that assess
the impact of clinical decision support interventions, but
without peer comparison.
Methods
Data, analytical methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
The project was approved by the Institutional Review Board
at the University of Massachusetts Medical School, and
waiver of consent was obtained.
Setting
The UMass-Memorial Medical Center is the largest not-for-
proﬁt healthcare system in Central Massachusetts with 1600
physicians and 13 500 employees. Its comprehensive network
of care includes a 3-campus academic medical center, 3 in-
network community hospitals, and several afﬁliated community
hospitals. The UMass-Memorial Medical Center has a large
ambulatory service footprint, with an effective catchment area
of nearly 1 million individuals. This nonproﬁt organization offers
a fully integrated healthcare continuum with a multicampus
academic medical center, member and afﬁliated community
hospitals, freestanding physician practices, and ambulatory
clinics. TheUMass-Memorial Medical Center used the Allscripts
ambulatory EMR (Allscripts, Inc, Chicago, IL)15 during the period
under study, that captures visit dates, billing codes, problem
lists (diagnostic codes), and is used to either document or
prescribe medication, including AC.
Population
First, we identiﬁed patients with AF based on their having an
International Classiﬁcation of Diseases, Tenth Revision (ICD-10)
code of I48.0, I48.1, I48.2, or I48.91 coded in the ambulatory
EMR.We then restricted our sample to focus on patients at high
stroke risk by identifying those patients with a CHA2DS2-VASc
stroke prediction score of 2 or more based on work by Lip
et al.16 This threshold was deﬁned on the basis of the fact that
multiple professional societies have deﬁned this risk score as
the optimal threshold to initiate AC to prevent ischemic
stroke.7,17 The CHA2DS2-VASc score assigns 1 point for
congestive heart failure, hypertension, age 65 to 74, diabetes
mellitus, vascular disease history likemyocardial infarction, and
female sex and 2 points for age 75+ or previous stroke or
transient ischemic attack. Our software calculated each
patient’s CHA2DS2-VASc score automatically using active
medical problems coded within the EMR. Speciﬁcally, we used
ICD-10 codes associated with outpatient clinical encounters
(Table S1). Furthermore, to be included in our study, AF patients
had to have at least 1 ambulatory visit in the past 12 months
with either a cardiology or primary care provider from our
medical group. The primary care providers in our sample
included healthcare providers from across several disciplines of
internal medicine, including family medicine or geriatrics, and
providers from multiple training backgrounds, including nurse
practitioners and medical doctors.
Provider Assignment
If an AF patient saw a cardiology provider (either nurse
practitioner or medical doctor) in the past 12 months, we
assigned the patient to him or her. This decision was made on
Clinical Perspective
What Is New?
• Electronic medical record–based messaging along with
e-mails can be used to prompt clinicians to review their
anticoagulation prescribing practices for their patients with
atrial ﬁbrillation.
What Are the Clinical Implications?
• Raising the percentage of anticoagulation use, however,
may require more than electronic messaging.
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the basis of a prespeciﬁed assumption that the patient’s PCP
would likely defer decision making regarding AC to the
treating cardiology provider. For all other AF patients with a
medical provider but no cardiology visits, we assigned the
patient to the primary care provider.
Determining AC Status
Every AF patient’s AC status was automatically coded as
“receiving AC,” if the EMR indicated that they had an active
prescription for warfarin/coumarin/Coumadin/or any vitamin
K antagonist, enoxaparin, dalteparin, dabigatran, rivaroxaban,
apixaban, or edoxaban at the time of the report. The same
report was run at baseline and after 10 weeks of intervention
for the intervention and control medical providers. As a way to
validate our identiﬁcation of AC status, we reviewed 100
charts manually and found that electronic capture of AC
status was highly accurate (sensitivity 95% and speciﬁcity
100%).
Design of Report With AC Percentage
We designed a graphical report that tracks providers’ change
in AC use over time following the Agency for Healthcare
Research and Quality’s handbook for developing performance
measurement tools.18 More speciﬁcally, we used Tableau
visual analytic software19 to create reports based on live data
in the Allscripts EMR to proﬁle AC prescription practices for
each provider included in our intervention group (Figure 1A).
The content of the report was based on the number of AF
patients at high risk for stroke seen within the past
12 months by the healthcare provider (≤10 versus >10). For
providers with more than 10 AF patients eligible for AC, in the
upper half of our proﬁle page, we displayed a bar graph
showing the percentage and number of eligible AF patients
currently receiving AC over the total number of AF patients
eligible for AC. We provided the report in this fashion to any
provider seeing more than 10 eligible patients. We superim-
posed 2 lines representing benchmarks on the bar graph to
enhance impact and help providers assess their prescription
rate. The ﬁrst line showed the percentage of AC prescription
for eligible AF patients among “peers,” using the average AC
use among eligible AF patients treated by cardiology or
primary care providers for cardiology and primary care
providers, respectively. We also included a second line at
80%, a target suggested by certain groups as a practice-level
AC prescription goal.20 For providers with 1 to 10 eligible
patients, we felt graphing performance would not be as
meaningful, and so we reported the percentage of AF patients
the provider had treated in the past 12 months without
providing a bar graph or peer comparison (Figure 1B). In the
lower half of the report, we included the medical record
numbers and stroke risk predictors for all AF patients eligible
but not currently receiving AC. We also included a list of AC-
eligible AF patients with appointments in the next 31 days to
focus providers on an actionable group of patients with whom
they might review the use of AC.
Design of EMR Message
We sent EMR messages from a user account created for our
study team to individual providers 1 day before any scheduled
appointment with an AC-eligible AF patient (Figure 2). The
EMR message was linked to the AF patient’s medical record,
facilitating review of patient charts by providers as well as
providing a format for providers to communicate back with
our team.
Intervention Groups
Based on strong support for our work within UMass-Memorial
Medical Center cardiovascular medicine and community-
based primary care leadership, we targeted providers from
these 2 groups to receive our AC intervention. As a ﬁrst step,
the chiefs of the 2 intervention cohorts distributed an e-mail
notifying their respective providers about our project and
impending distribution of reports by our group. One week
later, in July 2017, we sent e-mails with the report, ﬁrst to
cardiology providers, and then 2 weeks later to the commu-
nity-based primary care group. Subsequently, we sent 2
follow-up e-mails at 2-week intervals from the initial mailing.
These were identical to the ﬁrst e-mail in structure, but
included reports with updated AC information.
Because our institution moved to a new EMR in October
2017, we stopped sending AC-related practice proﬁle reports
and EMR messages in September 2017. Cardiology providers
received the intervention over a 10-week period and commu-
nity-based primary care over 8 weeks. This time period (July 1,
2017 to September 30, 2017) also served as our follow-up
period for the purpose of all our analyses.
Control Group
We did not deliver our intervention to an alternate group of
providers based at our university campus. The percentage of
AC use prescribed by these alternate providers served as
controls (reference) to the patients cared for by our interven-
tion providers in order to adjust for temporal trends in AC use.
The control group included patients seen by primary care
providers from the disciplines of general medicine, family
medicine, or geriatrics. Because we initiated the intervention
at different time points for cardiology versus community-
based primary care providers, the controls paired with each
intervention group differed slightly in order to conform to
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Figure 1. Example of report sent to providers caring for AC-eligible AF patients with CHA2DS2-VASc ≥2.
A, Sample report for providers with more than 10 eligible patients. MRN indicates medical record number;
UMass, University of Massachusetts. B, Sample report for providers with 10 or fewer eligible patients. AC
indicates anticoagulation; AF, atrial ﬁbrillation; MRN, medical record number. CHA2DS2-VASc conditions key:
C: Congestive Heart Failure, H: Hypertension, 75+: Age ≥75, D: Diabetes Mellitus, S: Stroke or Transient
Ischemic Attack, V: Vascular Disease, 65 to 74: Age 65 to 74, F: Female.
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inclusion criterion which required that each patient saw his or
her assigned provider within the past 12 months. Thereby,
the inception date for controls to the community-based
primary care providers lagged by 2 weeks compared with the
inception date for controls to the cardiology providers.
Outcomes
To assess feasibility of the intervention, we tabulated how
often providers in the intervention groups read our e-mails
with report of their AC percentage using Microsoft Outlook–
based read receipts. We also tracked how many providers
reviewed the EMR message items we sent them. Speciﬁcally,
if the provider replied to the EMR message or marked the
EMR message as complete, in progress, or removed, we
assumed that the EMR message had been reviewed. If the
provider did not reply and the EMR message remained
“active” in the provider’s inbox, we counted the EMR message
as not reviewed. Finally, we also tallied and thematically
coded providers’ reasons for not prescribing AC from
responses to our provider EMR messages.
To measure the effectiveness of our intervention on AC
use, we calculated the change in percentage of eligible
patients on AC for intervention and control groups.
Statistical Analysis
For our primary analyses, we only included patients with no
change in provider and who met the 12-month eligibility
criterion at baseline as well as at the end of the follow-up
period. Patients’ follow-up (postintervention) anticoagulation
status was modeled as a function of patients’ baseline
(preintervention) anticoagulation status, provider’s interven-
tion/control status, and CHA2DS2-VASc score. We hypothe-
sized that the change in AC percentage would be higher in
patients of intervention providers compared with those of
control providers. To account for within-provider clustering, we
used generalized estimation equation logistic regression.21 In
these analyses, patient AC status was modeled using gener-
alized estimation equation logistic regression as a function of
time period (baseline/follow-up), provider’s intervention or
control status, and their interaction, again adjusting for
CHA2DS2-VASc score. We hypothesized a statistically signif-
icant interaction, such that the follow-up versus baseline
difference in AC prescription percentage would be larger for
patients treated by intervention providers than for those
treated by control providers. To examine whether any inter-
vention-control difference varied by provider type, these
analyses were conducted separately for cardiology (interven-
tion) versus control providers and for community-based
primary care providers (intervention) versus control providers.
In both analyses, control providers were the same; the set of
control patients included varied slightly for the 2 analyses
because the 12-month inclusion criterion was applied 2 weeks
earlier for analyses including cardiology providers than for
analyses including community-based primary care providers.
In a sensitivity analysis, we included patients with a change
in provider or who met the 12-month inclusion criterion only
at baseline or only at follow-up (ie, the patient only
contributed to a provider’s percentage at baseline or follow-
up but not both). These analyses again were conducted
separately for cardiology providers versus controls and for
Figure 2. Screenshot of EMR message sent to providers 1 day before an appointment with an AC-eligible
AF patient. AC indicates anticoagulation; AF, atrial ﬁbrillation; EMR, electronic medical record.
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Table 1. Comparison of Key Characteristics Recorded at Beginning of Intervention for Patients From 3 Provider Groups
Characteristic
Cardiology Providers Community-Based Primary Care Providers Controls*
Frequency (% Out of 3786 Total) Frequency (% Out of 1054 Total) Frequency (% Out of 566 Total)
Age, y
75+ 2105 (55.6) 666 (63.2) 327 (57.8)
65 to 74 1262 (33.3) 312 (29.6) 161 (28.5)
<65 418 (11.0) 76 (7.2) 78 (13.8)
Female sex 1672 (44.2) 490 (46.5) 281 (50.0)
Median area-level annual income
≤100% poverty level 0 (0.0) 0 (0.0) 2 (0.4)
100% to 400% poverty level 2446 (65.0) 698 (66.4) 337 (60.8)
Nonwhite race 243 (6.4) 47 (4.5) 36 (6.4)
Hispanic ethnicity 78 (2.1) 16 (1.5) 17 (3.0)
Non-English-language preference 231 (6.1) 23 (2.2) 21 (3.7)
Insurance
Commercial 430 (11.4) 104 (9.9) 69 (12.2)
Medicare 3113 (82.2) 909 (86.2) 457 (80.7)
Medicaid 97 (2.6) 21 (2.0) 22 (3.9)
Other/MA state health insurance exchange 109 (2.9) 20 (1.9) 16 (2.8)
Uninsured/self-pay 37 (1.0) 0 (0.0) 2 (0.4)
Individual CHA2DS2-VASc comorbidities
CHF 1066 (28.2) 202 (19.2) 99 (17.5)
Hypertension 3046 (80.5) 870 (82.5) 442 (78.1)
Diabetes mellitus 972 (25.7) 310 (29.4) 182 (32.2)
Stroke/TIA 367 (9.7) 98 (9.3) 58 (10.3)
Vascular disease 1366 (36.1) 295 (28.0) 123 (21.7)
CHA2DS2-VASc score
2 741 (19.6) 200 (19.0) 127 (22.4)
3 953 (25.2) 248 (23.5) 158 (27.9)
4 1036 (27.4) 310 (29.4) 146 (25.8)
5 643 (17.0) 185 (17.6) 85 (15.0)
6 294 (7.8) 85 (8.1) 33 (5.8)
7 93 (2.5) 20 (1.9) 13 (2.3)
8 21 (0.6) 6 (0.6) 4 (0.7)
9 5 (0.1) 0 (0.0) 0 (0.0)
Anticoagulant use
Warfarin 1879 (49.6) 432 (41.0) 224 (39.6)
Direct oral anticoagulant 836 (22.1) 242 (23.0) 109 (19.3)
None 1071 (28.3) 380 (36.1) 233 (41.2)
Timing of visit with provider†
Early 407 (10.8) 144 (13.7) 95 (16.8)
Middle 423 (11.2) 163 (15.5) 85 (15.0)
Late 404 (10.7) 163 (15.5) 68 (12.0)
None 2552 (67.4) 584 (55.4) 318 (56.2)
Continued
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community-based primary care providers versus controls.
Finally, we re-examined the effect of our intervention in
several subsets. These included examining the effect in the
subset of patients who saw their assigned provider during the
intervention period, the subset of patients assigned to
providers who read varying numbers of our e-mails containing
the report with AC prescription percentage, the subset of
patients assigned to a provider who replied to multiple EMR
messages we sent, and the subset of patients with CHA2DS2-
VASc score of 2 or 3 and CHA2DS2-VASc score 4 or 5 (versus
CHA2DS2-VASc score 6+).
We performed all analyses in SAS software (version 9.4;
SAS Institute Inc, Cary, NC).22
Results
In July 2017 at study onset, we identiﬁed 3786 patients with
AF receiving care from cardiology providers and 562 treated
by controls. Two weeks later, at the time of study onset for
community-based primary care providers, we identiﬁed 1054
AF patients cared for by participating community-based
primary care providers as well as 566 treated by controls.
The number of AF patients with CHA2DS2-VASc score of 2, 3,
4, and 5+ was relatively evenly distributed across provider
groups (Table 1). Providers receiving our intervention cared
for AF patients with slightly higher CHA2DS2-VASc scores. The
proportion of AF patients treated with AC varied across
provider types, with cardiologists more frequently prescribing
AC for their eligible patients than primary care physicians in
both intervention and control groups. Cardiologists also saw a
considerably higher volume of AC-eligible AF patients, with
nearly 70% of providers seeing over 100 such patients, in
contrast to 0% among primary care providers in both
intervention and control groups (Table 1). Race and sex did
not vary signiﬁcantly across the provider groups. However,
primary care providers receiving the AC intervention did, on
average, see a higher proportion of patients over the age of
75 years.
We also compared patients receiving AC and those not
receiving AC for the same baseline characteristics. Patients
were comparable in age, income, race, and insurance. There
were more patients with CHA2DS2-VASc score ≥2 in the group
receiving AC. Patients off AC were more than twice as likely to
be under the care of a provider whose AC-eligible panel size
was 1 to 10 (Table 2).
In terms of feasibility of the e-mail component of our
intervention, we found that most patients received care from
a provider who read at least 1 of our e-mails. More
speciﬁcally, among patients receiving care from cardiology
providers, 676 (17.9%) received care from providers who read
1 e-mail and 1391 (36.7%) received care from providers who
read more than 1 of our e-mails. We observed similar trends
among patients receiving care from community-based primary
care providers (Table 3).
In terms of feasibility of the EMR message component of
our intervention, we found that providers reviewed our EMR
messages 96% of the time. We sent a total of 432 EMR
messages to 88 providers (31 cardiology providers and 57
community-based primary care providers) for upcoming
appointments with 362 unique patients over the course of
the intervention. Out of these 432 messages, we received 163
responses (or 37.5% response rate) from 64 unique providers
(19 cardiology and 45 community based). The 64 providers
who responded to our EMR-based messages cared for 51.7%
of all eligible AF patients not on AC. Overall, 77.3% of the
responses included reasons for not anticoagulating these
patients (Table 4). Of the 163 responses, healthcare providers
cited AF patient refusal to start/resume AC as the most
Table 1. Continued
Characteristic
Cardiology Providers Community-Based Primary Care Providers Controls*
Frequency (% Out of 3786 Total) Frequency (% Out of 1054 Total) Frequency (% Out of 566 Total)
Anticoagulation-eligible panel size of patient’s provider
1 to 10 51 (1.3) 249 (23.6) 230 (40.6)
11 to 50 558 (14.7) 689 (65.4) 336 (59.4)
51 to 100 643 (17.0) 116 (11.0) 0 (0.0)
>100 2534 (66.9) 0 (0.0) 0 (0.0)
CHF indicates congestive heart failure; TIA, transient ischemic attack.
*In the table, we report only the frequencies for patients serving as controls for community-based primary care providers. Controls for cardiology providers were mostly the same patients,
but because we rolled out the intervention 2 weeks earlier for cardiology providers, frequencies shifted slightly from 562 to 566 patients based on the requirement to have last
appointment within 12 months.
†
Early visit occurred between days 0 and 32 for cardiology and 0 and 29 for community-based primary care providers and controls; middle occurred between days 32 and 57 for cardiology
and 29 and 49 for community-based primary care providers and controls; ﬁnally, late visits occurred between days 57 and 79 for cardiology and 49 and 65 for community-based primary
care providers and controls.
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common reason for a patient not being on AC (21%), followed by
the provider’s perception that the patient was at a prohibitively
high risk for bleeding (19%) and deferral to primary cardiologist
or other physician (15%). Cardiologists and community-based
primary care providers both noted that patients refused AC
because they were worried about bleeding risks or other
adverse events, or knew someone who died from complications
of AC. Patient history of gastric bleeding, nose bleeding,
intracerebral bleeding, rectal bleeding, hematuria, and anemia
were among the reasons providers cited as explanations for
withholding AC. Of the 111 community-based primary care
providers’ responses to the EMRmessages, 24.3% deferred to a
cardiology specialist. These responses referred to notes in
which the patient’s cardiologist deemed ACwas unnecessary or
inappropriate, requested our research group to contact the
patient’s cardiologist instead, or informed us that the patient
would discuss treatment options with his or her cardiologist at a
future appointment.
At baseline, patients receiving care from cardiology
providers received AC at the highest percentage (71.3%)
followed by community-based primary care providers (63.5%)
followed by control providers (58.3%). At follow-up, there was
only a small change in the crude percentage of AC prescrip-
tion across all groups. Based on generalized estimation
equation logistic regression modeling, the adjusted change in
difference was not signiﬁcant for either intervention group
and was virtually unchanged from the unadjusted analysis.
Table 2. Comparison of Key Characteristics Recorded at
Beginning of Intervention for Patients on AC vs Patients Not
on AC
Characteristic
On AC Off AC
Frequency
(% Out of 3740 Total)
Frequency
(% Out of
1666 Total)
Age, y
75+ 2131 (57.0) 967 (58.0)
65 to 74 1228 (32.8) 507 (30.4)
<65 381 (10.2) 192 (11.5)
Female sex 1636 (43.7) 807 (48.4)
Median area-level annual income
≤100% poverty level 1 (0.0) 1 (0.1)
100% to 400% poverty level 2412 (64.9) 1069 (64.6)
Nonwhite race 236 (6.3) 90 (5.4)
Hispanic ethnicity 82 (2.2) 29 (1.7)
Non-English-language
preference
208 (5.6) 67 (4.0)
Insurance
Commercial 399 (10.7) 204 (12.2)
Medicare 3110 (83.2) 1369 (82.2)
Medicaid 96 (2.6) 44 (2.6)
Other/MA state health
insurance exchange
107 (2.9) 38 (2.3)
Uninsured/self-pay 28 (0.7) 11 (0.7)
Individual CHA2DS2-VASc comorbidities
CHF 1017 (27.2) 350 (21.0)
Hypertension 3040 (81.3) 1318 (79.1)
Diabetes mellitus 1058 (28.3) 406 (24.4)
Stroke/TIA 431 (11.5) 92 (5.5)
Vascular disease 1251 (33.4) 533 (32.0)
CHA2DS2-VASc score
2 668 (17.9) 400 (24.0)
3 939 (25.1) 420 (25.2)
4 1058 (28.3) 434 (26.1)
5 638 (17.1) 275 (16.5)
6 311 (8.3) 101 (6.1)
7 99 (2.6) 27 (1.6)
8 23 (0.6) 8 (0.5)
9 4 (0.1) 1 (0.1)
Anticoagulant use
Warfarin 2535 (67.8) N/A
Direct oral anticoagulant 1187 (37.7) N/A
Other 18 (0.5) N/A
Continued
Table 2. Continued
Characteristic
On AC Off AC
Frequency
(% Out of 3740 Total)
Frequency
(% Out of
1666 Total)
None N/A 1666 (100.0)
Timing of visit with provider*
Early 476 (12.7) 170 (10.2)
Middle 496 (13.3) 175 (10.5)
Late 497 (13.3) 138 (8.3)
None 2271 (60.7) 1183 (71.0)
AC-eligible panel size of patient’s provider
1 to 10 526 (14.1) 524 (31.5)
11 to 50 1146 (30.6) 581 (34.9)
51 to 100 394 (10.5) 338 (20.3)
>100 1674 (44.8) 223 (13.4)
AC indicates anticoagulation; AF, atrial ﬁbrillation; CHF, congestive heart failure; N/A,
not applicable; TIA, transient ischemic attack.
*Early visit occurred between days 0 and 32 for cardiology and 0 and 29 for community-
based primary care providers and controls; middle occurred between days 32 and 57 for
cardiology and 29 and 49 for community-based primary care providers and controls;
ﬁnally, late visits occurred between days 57 and 79 for cardiology and 49 and 65 for
community-based primary care providers and controls.
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More speciﬁcally, the difference between cardiology and
control group in adjusted AC percentage was 12.4% at
baseline and 12.3% at follow-up, a change in difference of
0.2% (P=0.91). The intracluster coefﬁcient for this analysis
was 0.014. The difference between community-based primary
care providers and controls was 5.1% at baseline and 5.1% at
the time of follow-up for a change in difference of 0.01%
(P=0.98). The intracluster coefﬁcient for this analysis was
0.032 (Table 5).
In the sensitivity analysis in which we included patients
with a change in provider (ie, who met the 12-month inclusion
criterion only at baseline or only at follow-up), there was
similarly no signiﬁcant change in AC percentage for interven-
tion groups relative to controls. More speciﬁcally, relative to
control providers, the change in AC percentage was 0.2%
higher for cardiology providers (P=0.82) and 0.8% lower for
community-based primary care providers (P=0.61).
Finally, there was no signiﬁcant effect of our intervention in
the various subsets that we examined. Speciﬁcally, compared
with the 0.2% change in difference in adjusted AC percent-
age from the main analysis of cardiology providers and 0.01%
in community-based primary care providers, in the subset of
patients seeing their assigned provider over the course of
follow-up, the change in difference value was 0.6% for patients
of cardiology providers and 0.06 for patients of community-
based primary care providers. Furthermore, there was no
signiﬁcant effect in the cohort of patients seeing their
provider in the ﬁrst 28 to 32 days of follow-up—change in
difference value of 0.8% for cardiology providers and 0.2%
for the community-based primary care providers. The change
in difference value was 1.0% in the patients cared for by the
subset of cardiology providers not reading any of our e-mails
to 0.9% for patients cared for by a provider who read more
than 1 of our e-mails. The same values in patients of
community-based primary care providers were 0.4% to 0.3%.
The change in difference in adjusted AC percentage was
0.55% for the subset of patients with a cardiology provider
who replied to multiple EMR messages (as opposed to a single
message or no message). This value was 0.06% for the
subset of community-based primary care providers who
replied to multiple EMR messages compared with controls.
Finally, the range for change in difference in adjusted AC
percentage was 0.6% for patients of cardiology providers
with CHA2DS2-VASc of 2 or 3 and 0.7 for patients of
cardiology providers with CHA2DS2-VASc of 6 or more. These
values were 0.1% to 0.3% for patients of community-based
primary care providers with CHA2DS2-VASc 2 or 3 and 6 or
more, respectively.
Discussion
We demonstrated that it is feasible to generate and distribute
reports of AC prescription percentages and EMR-based AC
Table 3. Frequency of Patients Receiving Care by Providers Reading Variable Number of E-mails
Provider Group No E-mail Read (%) One E-mail Read (%) More Than 1 E-mail Read (%) Total
Cardiology 1719 (45.4) 676 (17.9) 1391 (36.7) 3786
Community-based primary care providers 449 (42.6) 204 (19.4) 401 (38.0) 1054
Table 4. Distribution of Primary Reasons for Not Prescribing
AC Among Providers Responding to EMR Messages Sent as
Part of Prescriber Proﬁling Intervention (N=126*)
Reason*
Overall
Frequency (%)
N=102
Cardiology
N=38
Community-Based
Primary Care
N=64
No AF 5 (4.9) 1 (2.6) 4 (6.3)
Allergy with no
alternative
1 (1.0) 0 (0) 1 (1.6)
Hospice 2 (2.0) 0 (0) 2 (3.1)
Watchman/closure
of appendage
3 (2.9) 3 (7.9) 0 (0)
Active bleeding 1 (1.0) 0 (0) 1 (1.6)
Intralobar hemorrhage† 1 (1.0) 1 (2.6) 0 (0)
Other intracranial
hemorrhage
3 (2.9) 0 (0) 3 (4.7)
Patient not a good
candidate‡
2 (2.0) 0 (0) 2 (3.1)
Transient condition 17 (16.7) 6 (15.8) 11 (17.2)
Nonintracranial site
of bleeding
23 (22.5) 9 (23.7) 14 (21.9)
Patient already on dual
antiplatelet agent;
risk too high
1 (1.0) 1 (2.6) 0 (0)
Fall risk 8 (7.8) 2 (5.3) 6 (9.4)
Patient postablation 5 (4.9) 2 (5.3) 3 (4.7)
On aspirin 5 (4.9) 0 (0) 5 (7.8)
Patient refusal 25 (24.5) 13 (34.2) 12 (18.8)
AC indicates anticoagulation; AF, atrial ﬁbrillation; EMR, electronic medical record.
*We received 163 responses to our EMR messages, out of which 126 included reasons
for not prescribing AC.
†
Hemorrhage into frontal, parietal, occipital, or temporal lobes; distinctive from deep
brain hematoma involving midbrain, also subarachnoid hemorrhage.
‡
Patient nonadherent, has intellectual disability or poor cognitive status and no one to
supervise medication, poor AC control, or poor experience with warfarin in the past.
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messages to primary care and cardiology providers respon-
sible for treating AF patients within our health system.
Involvement of our health system’s informatics and leadership
teams was essential to our ability to generate automated
processes for AF patient identiﬁcation and stroke risk
proﬁling. Providers were most likely to review and respond
to EMR messages as compared with e-mails. Patient refusal,
high bleeding risk, and deference to a cardiology specialist
were the most common reasons provided by providers for not
treating their AF patients with AC. We did not detect an
increase in AC use among intervention providers relative to
controls.
Several other provider-directed intervention studies have
addressed AC prescription among AF patients. Three recent
trials12–14 found mixed results for clinical decision support,
although the trial12 which obligated intervention providers to
explain why his or her patient was not on AC achieved a 1.6%
increase in rate of AC use compared with control providers. In
1 cluster-randomized, multisite trial conducted in the United
States,23 there was no added beneﬁt of site visits and direct
engagement with providers compared with the distribution of
paper-based reports of AC prescription percentages. Of note,
the study follow-up for that trial was 2 years, much longer
than the 8 to 10 weeks available to us for follow-up. In
another UK-based cluster trial24,25 looking at direct engage-
ment with educational meetings and visits there was a 10%
increase in the proportion of patients with guideline-
concordant AC and aspirin use among those with AF,
although like our study, the result was not statistically
signiﬁcant. More recently, investigators conducting the
IMPACT-AF (Integrated Management Program Advancing
Community Treatment of Atrial Fibrillation) cluster-rando-
mized, multinational study25 found that education of patients
and providers in 5 middle-income countries with regular
monitoring and feedback increased AC use among interven-
tion patients by 9.1% more than controls. Individual countries
were able to customize the educational content and mode of
delivery, including use of digital and social media. Our
intervention leveraged tools available through the EMR and
external software that were not available to, or used by, the
previous investigative groups. By contrast, we did not directly
engage providers (ie we did not meet with them in person),
which had mixed results in the studies cited above.
Responses to EMR messages we sent suggest that providers
could beneﬁt from discussion with trusted advisors regarding
controversial areas and important topics, including shared
decision-making practices, issues of frailty and fall risk in
relation to AC beneﬁt, initiation of AC for AF that developed
during a transient illness or surgery, and safe practices around
AC resumption after a bleeding event. Increasing AC use may
therefore require a combination of technology-based
approaches and direct engagement with providers. Finally,
we did not directly interact with AF patients. Given the
success of IMPACT-AF, which interacted directly with
patients, and our own ﬁndings that a number of providers
indicated patient refusal as a reason for not starting/
resuming AC, other researchers developing interventions in
this area may decide to include a component of direct
interaction with patients.
Understanding the lack of impact of our ﬁndings can
beneﬁt from discussion of strategies suggested by experts in
a published article for improving effectiveness when delivering
practice-based feedback.26 As recommended by the authors
of this article, we obtained endorsement of clinical chiefs
supervising providers whose practice we proﬁled. At the same
time, we did not widely solicit feedback from individual
providers about the priority of our intervention relative to
other quality improvement efforts/other priorities. We pro-
vided multiple instances of feedback including 3 e-mails and
separately EMR messages on each occurrence of a patient
not on AC visiting his or her provider. We also provided
feedback both quantitatively and visually. As mentioned
above, we did not directly engage providers, which likely
limited our impact.
There are other limitations to the ﬁndings we report. We had
a short follow-up period (8–10 weeks), and it is possible that if
Table 5. Comparison of Change in the Difference in Adjusted Percentage on Anticoagulation for Patients Cared for by Cardiology
and Community-Based Primary Care Providers Versus Controls
Provider Group
At Baseline (Preintervention) At Follow-up (Postintervention) Change in the
Difference
at Follow-up vs
Baseline %
Adjusted Percentage
on Anticoagulation
Difference in Adjusted Percentage
on Anticoagulation From Controls
Adjusted Percentage
on Anticoagulation
Difference in Adjusted Percentage
on Anticoagulation From Controls
Cardiology (n=3786) 71.3 12.4 71.5 12.3 0.2 (P=0.91)
Community (n=1054) 63.5 5.1 63.7 5.1 0.01 (P=0.98)
Controls (n=566)* 58.9 Reference 59.2 Reference Reference
*In the table, we report only the frequencies for patients serving as controls for community-based primary care providers. Controls for cardiology providers were mostly the same patients,
but because we rolled out the intervention 2 weeks earlier for cardiology providers, frequencies shifted slightly from 562 to 566 patients based on the requirement to have last
appointment within 12 months.
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we had longer to follow AC prescribing, we would have had seen
a larger impact. Approximately 40% of patients saw their
assigned provider over the duration of the study. We anticipate
that with 6 months of follow-up, nearly every patient would
have seen his provider given typical follow-up for a patient with
AF on AC. The considerably higher average AC rates among
cardiology and community-based intervention providers at
baseline comparedwith control providers also limited our ability
to detect a signiﬁcant change in AC prescription. Perhaps,
targeting providers with lower AC use would have enabled us to
observe a more-substantial increase in AC rates with our
intervention. Unfortunately, our health system’s transition to
another EMR system limited our ability to identify AF patients,
proﬁle their stroke risk, and deliver scripted messages in an
uninterrupted fashion. To address this limitation, we looked at a
subset of patients who were seen over the course of the
intervention and compared the effect with that of the entire
sample (most of whom were not seen during the course of the
intervention). The subset analysis, however, did not suggest a
more-positive effect. Other limitations include potential for
residual confounding from the older age seen in community-
based primary care providers and also from the lower rate of AC
use at baseline in the control population. Our inability to identify
the discrete effectiveness of each component of the interven-
tion and absence of information about bleed or fall risk in our AC
proﬁling process are other limitations. The subset analysis
mentioned above does provide important information about the
effectiveness of the EMRmessages sent before ofﬁce visitswith
AF patients, but it is difﬁcult to disentangle EMR message
effects from the e-mails with reports of AC prescription
percentages. We also did not provide clinicians receiving
reports with information about bleeding or fall risk/history for
their patients. We plan to provide this in our future work.
In summary, we conﬁrmed the feasibility of proﬁling AC
prescription practices for AF patients among ambulatory
healthcare providers using a common EMR. Although we did
not ﬁnd a signiﬁcant effect for our 2-component intervention,
responses from providers, our process evaluation, and our
analysis methodology allow us and others to determine the
comparative effectiveness of future interventions focused on
improving AC prescription practice. Based on our ﬁndings, we
suspect that proﬁling and EMRmessaging alone is not sufﬁcient
to overcome the AC prescription gap among eligible AF
patients. Future work should examine the role of direct
engagement with providers, focusing on the reasons for not
prescribing AC that providers reported to us in the current work.
Acknowledgments
This study was supported by the Center for Data Driven Discovery
and HealthCare (D³Health) at the University of Massachusetts
Medical School. The data and conclusions derived from this study
are solely the responsibility of the authors and do not necessarily
represent the ofﬁcial views of D³Health or the medical school.
Sources of Funding
This study was funded by a grant from Bristol-Myers Squibb
under the request ID 28358345.
Disclosures
Dr Kapoor receives sponsored research support from Bristol-
Myers Squibb for the currently submitted project and has
received similar support in the past from Pﬁzer. Dr McManus
receives sponsored research support from Bristol-Myers
Squibb, Pﬁzer, Biotronik, and Philips Healthcare and has
consulted for Bristol-Myers Squibb, FlexCon, Samsung,
Philips, and Pﬁzer. Dr McManus has equity in Mobile Sense
Technologies, LLC. Dr Lubitz receives sponsored research
support from Bristol-Myers Squibb, Bayer HealthCare, Bio-
tronik, and Boehringer Ingelheim and has consulted for St.
Jude Medical/Abbott and Quest Diagnostics. All other authors
have declared that they do not have any potential conﬂicts of
interest.
References
1. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current
and future incidence and prevalence of atrial ﬁbrillation in the U.S. adult
population. Am J Cardiol. 2013;112:1142–1147.
2. Miyasaka Y, Barnes ME, Bailey KR, Cha SS, Gersh BJ, Seward JB, Tsang TS.
Mortality trends in patients diagnosed with ﬁrst atrial ﬁbrillation: a 21-year
community-based study. J Am Coll Cardiol. 2007;49:986–992.
3. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de
Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela
BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB,
McGuire DK, Mohler ER III, Moy CS, Muntner P, Mussolino ME, Nasir K,
Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ,
Sorlie PD, Stein J, Towﬁghi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW,
Turner MB. Heart Disease and Stroke Statistics—2015 update: a report from
the American Heart Association. Circulation. 2015;131:e29–e322.
4. Heart and Stroke Foundation of Canada. “Atrial ﬁbrillation”. 2016. Available at:
http://www.heartandstroke.ca/heart/conditions/atrial-ﬁbrillation. Accessed
June 19, 2016.
5. Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, Silver FL, Kapral
MK. Potentially preventable strokes in high-risk patients with atrial ﬁbrillation
who are not adequately anticoagulated. Stroke. 2009;40:235–240.
6. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral
anticoagulants in atrial ﬁbrillation: a systematic review. Am J Med.
2010;123:638–645.e4.
7. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti
JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG,
Tchou PJ, Tracy CM, Yancy CW. 2014 AHA/ACC/HRS guideline for the
management of patients with atrial ﬁbrillation: executive summary: a report of
the American College of Cardiology/American Heart Association Task Force
on practice guidelines and the Heart Rhythm Society. Circulation.
2014;130:2071–2104.
8. Marcucci M, Nobili A, Tettamanti M, Iorio A, Pasina L, Djade CD, Franchi C,
Marengoni A, Salerno F, Corrao S, Violi F, Mannucci PM. Joint use of cardio-
embolic and bleeding risk scores in elderly patients with atrial ﬁbrillation. Eur J
Intern Med. 2013;24:800–806.
9. Steinberg BA, Kim S, Thomas L, Fonarow GC, Hylek E, Ansell J, Go AS, Chang P,
Kowey P, Gersh BJ, Mahaffey KW, Singer DE, Piccini JP, Peterson ED. Lack of
concordance between empirical scores and physician assessments of stroke
and bleeding risk in atrial ﬁbrillation: results from the Outcomes Registry for
DOI: 10.1161/JAHA.118.009946 Journal of the American Heart Association 11
SUPPORT-AF Study Kapoor et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on November 15, 2018
Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation.
2014;129:2005–2012.
10. Hsu JC, Chan PS, Tang F, Maddox TM, Marcus GM. Oral anticoagulant
prescription in patients with atrial ﬁbrillation and a low risk of thromboem-
bolism: insights from the NCDR PINNACLE Registry. JAMA Intern Med.
2015;175:1062–1065.
11. Khurshid S, Keaney J, Ellinor PT, Lubitz SA. A simple and portable algorithm for
identifying atrial ﬁbrillation in the electronic medical record. Am J Cardiol.
2016;117:221–225.
12. Karlsson LO, Nilsson S, Bang M, Nilsson L, Charitakis E, Janzon M. A clinical
decision support tool for improving adherence to guidelines on anticoagulant
therapy in patients with atrial ﬁbrillation at risk of stroke: a cluster-randomized
trial in a Swedish primary care setting (the CDS-AF study). PLoS Med.
2018;15:e1002528.
13. Holt TA, Dalton A, Marshall T, Fay M, Qureshi N, Kirkpatrick S, Hislop J,
Lasserson D, Kearley K, Mollison J, Yu LM, Hobbs FD, Fitzmaurice D.
Automated software system to promote anticoagulation and reduce stroke
risk: cluster-randomized controlled trial. Stroke. 2017;48:787–790.
14. Arts DL, Abu-Hanna A, Medlock SK, van Weert HC. Effectiveness and usage of
a decision support system to improve stroke prevention in general practice: a
cluster randomized controlled trial. PLoS One. 2017;12:e0170974.
15. Allscripts [computer program]. Chicago, IL: Allscripts Healthcare Solutions,
Inc.; 1986.
16. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Reﬁning clinical risk
stratiﬁcation for predicting stroke and thromboembolism in atrial ﬁbrillation
using a novel risk factor-based approach: the Euro Heart Survey on atrial
ﬁbrillation. Chest. 2010;137:263–272.
17. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M,
Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J,
Alexandru Popescu B, Schotten U, Van Putte B, Vardas P. 2016 ESC guidelines
for the management of atrial ﬁbrillation developed in collaboration with
EACTS. Rev Esp Cardiol (Engl Ed). 2017;70:50.
18. Module 7. Measuring and benchmarking clinical performance. Rockville, MD:
Agency for Healthcare Research and Quality (AHRQ). Content last reviewed
May 2013. Available at: http://www.ahrq.gov/professionals/prevention-
chronic-care/improve/system/pfhandbook/mod7.html. Accessed April 26,
2018.
19. Tableau [computer program]. Seattle, WA: Tableau Software; 2003.
20. Cullen MW, Kim S, Piccini JP Sr, Ansell JE, Fonarow GC, Hylek EM, Singer DE,
Mahaffey KW, Kowey PR, Thomas L, Go AS, Lopes RD, Chang P, Peterson
ED, Gersh BJ. Risks and beneﬁts of anticoagulation in atrial ﬁbrillation:
insights from the Outcomes Registry for Better Informed Treatment of Atrial
Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes. 2013;6:
461–469.
21. Molenberghs G, Verbeke G. Models for Discrete Longitudinal Data. New York,
NY: Springer-Verlag; 2005.
22. SAS [computer program]. Cary, NC: SAS Institute; 2013.
23. Ornstein S, Jenkins RG, Nietert PJ, Feifer C, Roylance LF, Nemeth L, Corley S,
Dickerson L, Bradford WD, Litvin C. A multimethod quality improvement
intervention to improve preventive cardiovascular care: a cluster randomized
trial. Ann Intern Med. 2004;141:523–532.
24. Wright J, Bibby J, Eastham J, Harrison S, McGeorge M, Patterson C, Price N,
Russell D, Russell I, Small N, Walsh M, Young J. Multifaceted implementation
of stroke prevention guidelines in primary care: cluster-randomised evaluation
of clinical and cost effectiveness. Qual Saf Health Care. 2007;16:51–59.
25. Ezekowitz MD, Kent AP. The impact of IMPACT-AF. Lancet. 2017;390:1717–
1718.
26. Brehaut JC, Colquhoun HL, Eva KW, Carroll K, Sales A, Michie S, Ivers N,
Grimshaw JM. Practice feedback interventions: 15 suggestions for optimizing
effectiveness. Ann Intern Med. 2016;164:435–441.
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
DOI: 10.1161/JAHA.118.009946 Journal of the American Heart Association 12
SUPPORT-AF Study Kapoor et al
D
ow
nloaded from
 http://ahajournals.org by on November 15, 2018
SUPPLEMENTAL MATERIAL
D
ow
nloaded from
 http://ahajournals.org by on November 15, 2018
Table S1. ICD-10 Diagnosis Codes for Atrial Fibrillation and CHA2DS2-VASc 
Predictors.
CHA2DS2-VASc 
Predictors 
ICD-10 Code in 
Allscripts 
ICD-10 Code Name 
Atrial Fibrillation I48.0 Paroxysmal atrial fibrillation 
I48.1 Persistent atrial fibrillation 
I48.2 Chronic atrial fibrillation 
I48.91 Unspecified atrial fibrillation 
Congestive Heart 
Failure 
I50.1 Left ventricular failure, unspecified 
I50.9 Heart failure, unspecified 
Hypertension I10 Essential (primary) hypertension 
I11.0 Hypertensive Heart Disease With Heart Failure 
I11.9 Hypertensive Heart Disease Without Heart Failure 
I12.0 Hypertensive Chronic Kidney Disease With Stage 5 
Chronic Kidney Disease Or End Stage Renal Disease 
I12.9 Hypertensive Chronic Kidney Disease With Stage 1 
Through Stage 4 Chronic Kidney Disease, Or 
Unspecified Chronic Kidney Disease 
I13.0 Hypertensive Heart And Chronic Kidney Disease With 
Heart Failure And Stage 1 Through Stage 4 Chronic 
Kidney Disease, Or Unspecified Chronic Kidney 
Disease 
I13.10 Hypertensive Heart And Chronic Kidney Disease 
Without Heart Failure, With Stage 1 Through Stage 4 
Chronic Kidney Disease, Or Unspecified Chronic 
Kidney Disease 
I13.11 Hypertensive Heart And Chronic Kidney Disease 
Without Heart Failure, With Stage 5 Chronic Kidney 
Disease, Or End Stage Renal Disease 
I13.2 Hypertensive Heart And Chronic Kidney Disease With 
Heart Failure And With Stage 5 Chronic Kidney 
Disease, Or End Stage Renal Disease 
I15.0 Renovascular Hypertension 
I15.1 Hypertension Secondary To Other Renal Disorders 
I15.2 Hypertension Secondary To Endocrine Disorders 
I15.8 Other Secondary Hypertension 
I15.9 Secondary Hypertension, Unspecified 
Diabetes E10.10 Type 1 Diabetes Mellitus With Ketoacidosis Without 
Coma 
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 E10.11     Type 1 Diabetes Mellitus With Ketoacidosis With 
Coma 
 E10.21     Type 1 Diabetes Mellitus With Diabetic Nephropathy 
 E10.22     Type 1 Diabetes Mellitus With Diabetic Chronic 
Kidney Disease 
 E10.29     Type 1 Diabetes Mellitus With Other Diabetic Kidney 
Complication 
 E10.31x  Type 1 Diabetes Mellitus With Unspecified Diabetic 
Retinopathy 
 E10.32x Type 1 Diabetes Mellitus With Mild Nonproliferative 
Diabetic Retinopathy 
 E10.33x Type 1 Diabetes Mellitus With Moderate 
Nonproliferative Diabetic Retinopathy 
 E10.34x Type 1 Diabetes Mellitus With Severe 
Nonproliferative Diabetic Retinopathy 
 E10.35x Type 1 Diabetes Mellitus With Proliferative Diabetic 
Retinopathy 
 E10.36     Type 1 Diabetes Mellitus With Diabetic Cataract 
 E10.37Xx   Type 1 Diabetes Mellitus With Diabetic Macular 
Edema, Resolved Following Treatment 
 E10.39     Type 1 Diabetes Mellitus With Other Diabetic 
Ophthalmic Complication 
 E10.40     Type 1 Diabetes Mellitus With Diabetic Neuropathy, 
Unspecified 
 E10.41     Type 1 Diabetes Mellitus With Diabetic 
Mononeuropathy 
 E10.42     Type 1 Diabetes Mellitus With Diabetic 
Polyneuropathy 
 E10.43     Type 1 Diabetes Mellitus With Diabetic Autonomic 
(Poly)Neuropathy 
 E10.44     Type 1 Diabetes Mellitus With Diabetic Amyotrophy 
 E10.49     Type 1 Diabetes Mellitus With Other Diabetic 
Neurological Complication 
 E10.51     Type 1 Diabetes Mellitus With Diabetic Peripheral 
Angiopathy Without Gangrene 
 E10.52     Type 1 Diabetes Mellitus With Diabetic Peripheral 
Angiopathy With Gangrene 
 E10.59     Type 1 Diabetes Mellitus With Other Circulatory 
Complications 
 E10.610    Type 1 Diabetes Mellitus With Diabetic Neuropathic 
Arthropathy 
 E10.618    Type 1 Diabetes Mellitus With Other Diabetic 
Arthropathy 
 E10.620    Type 1 Diabetes Mellitus With Diabetic Dermatitis 
 E10.621    Type 1 Diabetes Mellitus With Foot Ulcer 
 E10.622    Type 1 Diabetes Mellitus With Other Skin Ulcer 
 E10.628    Type 1 Diabetes Mellitus With Other Skin 
Complications 
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 E10.630    Type 1 Diabetes Mellitus With Periodontal Disease 
 E10.638    Type 1 Diabetes Mellitus With Other Oral 
Complications 
 E10.641    Type 1 Diabetes Mellitus With Hypoglycemia With 
Coma 
 E10.649    Type 1 Diabetes Mellitus With Hypoglycemia Without 
Coma 
 E10.65     Type 1 Diabetes Mellitus With Hyperglycemia 
 E10.69     Type 1 Diabetes Mellitus With Other Specified 
Complication 
 E10.8      Type 1 Diabetes Mellitus With Unspecified 
Complications 
 E10.9      Type 1 Diabetes Mellitus Without Complications 
 E11.00     Type 2 Diabetes Mellitus With Hyperosmolarity 
Without Nonketotic Hyperglycemic-Hyperosmolar 
Coma (Nkhhc) 
 E11.01     Type 2 Diabetes Mellitus With Hyperosmolarity With 
Coma 
 E11.21     Type 2 Diabetes Mellitus With Diabetic Nephropathy 
 E11.22     Type 2 Diabetes Mellitus With Diabetic Chronic 
Kidney Disease 
 E11.29     Type 2 Diabetes Mellitus With Other Diabetic Kidney 
Complication 
 E11.31x  Type 2 Diabetes Mellitus With Unspecified Diabetic 
Retinopathy 
 E11.32x Type 2 Diabetes Mellitus With Mild Nonproliferative 
Diabetic Retinopathy 
 E11.33x    
 
Type 2 Diabetes Mellitus With Moderate 
Nonproliferative Diabetic Retinopathy 
 E11.34x Type 2 Diabetes Mellitus With Severe 
Nonproliferative Diabetic Retinopathy 
 E11.35x Type 2 Diabetes Mellitus With Proliferative Diabetic 
Retinopathy 
 E11.36     Type 2 Diabetes Mellitus With Diabetic Cataract 
 E11.37Xx   Type 2 Diabetes Mellitus With Diabetic Macular 
Edema, Resolved Following Treatment 
 E11.39     Type 2 Diabetes Mellitus With Other Diabetic 
Ophthalmic Complication 
 E11.40     Type 2 Diabetes Mellitus With Diabetic Neuropathy, 
Unspecified 
 E11.41     Type 2 Diabetes Mellitus With Diabetic 
Mononeuropathy 
 E11.42     Type 2 Diabetes Mellitus With Diabetic 
Polyneuropathy 
 E11.43     Type 2 Diabetes Mellitus With Diabetic Autonomic 
(Poly)Neuropathy 
 E11.44     Type 2 Diabetes Mellitus With Diabetic Amyotrophy 
 E11.49     Type 2 Diabetes Mellitus With Other Diabetic 
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Neurological Complication 
 E11.51     Type 2 Diabetes Mellitus With Diabetic Peripheral 
Angiopathy Without Gangrene 
 E11.52     Type 2 Diabetes Mellitus With Diabetic Peripheral 
Angiopathy With Gangrene 
 E11.59     Type 2 Diabetes Mellitus With Other Circulatory 
Complications 
 E11.610    Type 2 Diabetes Mellitus With Diabetic Neuropathic 
Arthropathy 
 E11.618    Type 2 Diabetes Mellitus With Other Diabetic 
Arthropathy 
 E11.620    Type 2 Diabetes Mellitus With Diabetic Dermatitis 
 E11.621    Type 2 Diabetes Mellitus With Foot Ulcer 
 E11.622    Type 2 Diabetes Mellitus With Other Skin Ulcer 
 E11.628    Type 2 Diabetes Mellitus With Other Skin 
Complications 
 E11.630    Type 2 Diabetes Mellitus With Periodontal Disease 
 E11.638    Type 2 Diabetes Mellitus With Other Oral 
Complications 
 E11.641    Type 2 Diabetes Mellitus With Hypoglycemia With 
Coma 
 E11.649    Type 2 Diabetes Mellitus With Hypoglycemia Without 
Coma 
 E11.65     Type 2 Diabetes Mellitus With Hyperglycemia 
 E11.69     Type 2 Diabetes Mellitus With Other Specified 
Complication 
 E11.8      Type 2 Diabetes Mellitus With Unspecified 
Complications 
 E11.9      Type 2 Diabetes Mellitus Without Complications 
 E13.x Other Specified Diabetes Mellitus 
   
Stroke/TIA/ 
Thromboembolism 
G45.9 Transient cerebral ischemic attack, unspecified. 
 I63.0x, I63.3x Cerebral Infarction Due To Thrombosis 
 I63.1x, I63.4x Cerebral Infarction Due To Embolism 
 I63.2x, I63.5x Cerebral Infarction Due To Unspecified Occlusion Or 
Stenosis 
 I63.6      Cerebral Infarction Due To Cerebral Venous 
Thrombosis, Nonpyogenic 
 I63.8      Other Cerebral Infarction 
 I63.9      Cerebral Infarction, Unspecified 
 I74.01     Saddle Embolus Of Abdominal Aorta 
 I74.09     Other Arterial Embolism And Thrombosis Of 
Abdominal Aorta 
 I74.x (x = 1 to 9) Embolism And Thrombosis 
   
Vascular Disease I21.x (x = 0 to 3)  St Elevation (STEMI) Myocardial Infarction 
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 I21.4      Non-St Elevation (NSTEMI) Myocardial Infarction 
 I22.0, I22.1, 
I22.8, I22.9      
Subsequent St Elevation (STEMI) Myocardial 
Infarction 
 I22.2      Subsequent Non-St Elevation (NSTEMI) Myocardial 
Infarction 
 I25.2      Old Myocardial Infarction 
 I25.10, I25.11x     Atherosclerotic Heart Disease Of Native Coronary 
Artery 
 I70.20x Unspecified Atherosclerosis Of Native Arteries Of 
Extremities 
 I70.21x  Atherosclerosis Of Native Arteries Of Extremities With 
Intermittent Claudication 
 I70.22x  Atherosclerosis Of Native Arteries Of Extremities With 
Rest Pain 
 I70.23x  Atherosclerosis Of Native Arteries Of Right Leg With 
Ulceration 
 I70.24x    Atherosclerosis Of Native Arteries Of Left Leg With 
Ulceration 
 I70.25     Atherosclerosis Of Native Arteries Of Other 
Extremities With Ulceration 
 I70.0      Atherosclerosis Of Aorta 
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